The long wait for targeted systemic therapies to manage desmoid tumors could be over after a second drug directed against the Notch pathway has shown promise.
Nirogacestat showed improved progression-free survival, pain scores, symptoms, and quality of life in patients with progressive desmoid tumors in a phase 3 trial hailed as practice changing.
Radiation-induced sarcoma (RIS) is a rare but aggressive complication of radiotherapy. This study was published as a preprint and has not yet been peer reviewed.